Shares of Septerna, Inc. (NASDAQ:SEPN - Get Free Report) were up 12.2% during mid-day trading on Thursday . The stock traded as high as $17.62 and last traded at $17.45. Approximately 106,955 shares were traded during trading, a decline of 46% from the average daily volume of 197,869 shares. The stock had previously closed at $15.55.
Wall Street Analysts Forecast Growth
Several brokerages recently commented on SEPN. JPMorgan Chase & Co. started coverage on shares of Septerna in a research note on Tuesday, November 19th. They set an "overweight" rating and a $38.00 price objective for the company. TD Cowen assumed coverage on Septerna in a report on Tuesday, November 19th. They set a "buy" rating for the company. Cantor Fitzgerald assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an "overweight" rating and a $50.00 target price for the company. Finally, Wells Fargo & Company began coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an "overweight" rating and a $43.00 price target on the stock.
Read Our Latest Research Report on SEPN
Septerna Stock Down 7.7 %
The firm has a 50 day simple moving average of $21.55.
Hedge Funds Weigh In On Septerna
Several institutional investors and hedge funds have recently modified their holdings of the company. Rhumbline Advisers acquired a new stake in shares of Septerna in the fourth quarter valued at about $458,000. New York State Common Retirement Fund bought a new stake in shares of Septerna during the fourth quarter valued at approximately $32,000. Finally, SG Americas Securities LLC bought a new position in shares of Septerna in the fourth quarter valued at approximately $185,000.
About Septerna
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Featured Stories
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
